Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) COO Julie Rubinstein sold 11,466 shares of the business’s stock in a transaction dated Friday, November 13th. The stock was sold at an average price of $28.93, for a total value of $331,711.38. Following the transaction, the chief operating officer owned 377,802 shares of the company’s stock, valued at $10,929,811.86. The trade was a 2.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Julie Rubinstein also recently made the following trade(s):
- On Thursday, November 12th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $29.40, for a total value of $349,301.40.
- On Monday, November 9th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $30.12, for a total transaction of $357,855.72.
- On Thursday, November 5th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $26.53, for a total transaction of $315,202.93.
- On Friday, October 30th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $26.73, for a total transaction of $317,579.13.
- On Monday, November 2nd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.47, for a total transaction of $302,609.07.
- On Wednesday, October 28th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $28.45, for a total transaction of $338,014.45.
- On Monday, October 26th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $26.04, for a total value of $309,381.24.
- On Friday, October 23rd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $24.98, for a total value of $296,787.38.
- On Monday, October 19th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $24.05, for a total value of $285,738.05.
- On Wednesday, October 21st, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.41, for a total value of $301,896.21.
Adaptive Biotechnologies Stock Down 1.5%
Shares of ADPT traded down $0.44 on Friday, hitting $29.04. The company’s stock had a trading volume of 2,063,725 shares, compared to its average volume of 2,197,728. The company has a quick ratio of 3.87, a current ratio of 3.97 and a debt-to-equity ratio of 1.82. The firm’s fifty day moving average price is $26.91 and its 200-day moving average price is $20.13. Adaptive Biotechnologies Corporation has a fifty-two week low of $12.00 and a fifty-two week high of $32.21. The firm has a market capitalization of $4.70 billion, a price-to-earnings ratio of -64.53 and a beta of 2.18.
Institutional Trading of Adaptive Biotechnologies
Hedge funds and other institutional investors have recently made changes to their positions in the business. Entropy Technologies LP boosted its holdings in Adaptive Biotechnologies by 207.2% during the third quarter. Entropy Technologies LP now owns 62,438 shares of the company’s stock worth $1,804,000 after purchasing an additional 42,113 shares during the last quarter. FORA Capital LLC bought a new position in Adaptive Biotechnologies in the third quarter valued at $443,000. Empowered Funds LLC bought a new position in Adaptive Biotechnologies in the third quarter valued at $9,559,000. Caxton Associates LLP bought a new position in Adaptive Biotechnologies in the third quarter valued at $741,000. Finally, First Trust Advisors LP increased its stake in Adaptive Biotechnologies by 90.8% in the 3rd quarter. First Trust Advisors LP now owns 797,309 shares of the company’s stock valued at $23,042,000 after buying an additional 379,486 shares during the last quarter. 99.17% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several brokerages have recently issued reports on ADPT. TD Cowen increased their price objective on shares of Adaptive Biotechnologies from $28.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, October 13th. BTIG Research raised their price objective on shares of Adaptive Biotechnologies from $25.00 to $34.00 and gave the stock a “buy” rating in a report on Tuesday, September 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Thursday, October 15th. National Bank Financial set a $34.00 target price on shares of Adaptive Biotechnologies in a research note on Tuesday, September 22nd. Finally, Piper Sandler upped their target price on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the stock an “overweight” rating in a research note on Tuesday, August 4th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $30.31.
Check Out Our Latest Stock Analysis on ADPT
Adaptive Biotechnologies Company Profile
Adaptive Biotechnologies is a biotechnology company focused on using the human immune system to diagnose and treat disease. Based in Seattle, Washington, the company develops technologies that sequence and analyze immune cells and their receptors, generating data for clinical testing, research and drug development. Its products include immunoSEQ, a platform used by researchers and biopharmaceutical companies to study immune responses, and clonoSEQ, a clinical test that detects and monitors minimal residual disease in certain blood cancers.
Recommended Stories
- Five stocks we like better than Adaptive Biotechnologies
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
